Factor de transferencia parte 3 ¿Qué hace?
Channel: Dr. Teoto
Date: 2020-02-01

Qué efectos tiene el factor de transferencia sobre diversas enfermedades ¿Realmente sirve en enfermedades autoinmunes?

BIBLIOGRAFÍA:
1. Viza D, Fudenberg HH, Palareti A, Ablashi D, De Vinci C, Pizza G.Folia Biol (Praha). Transfer factor: an overlooked potential for the prevention and treatment of infectious diseases.2013;59(2):53-67.
2. Sánchez-González DJ, Sosa-Luna CA, Vásquez-Moctezuma I. [Transfer factors in medical therapy].Med Clin (Barc). 2011 Sep 10;137(6):273-7. doi: 10.1016/j.medcli.2010.05.002. 
3.Mardirossian M, Sola R, Beckert B, Collis DWP, Di Stasi A, et al.  Proline-Rich Peptides with Improved Antimicrobial Activity against E. coli, K. pneumoniae, and A. baumannii. ChemMedChem. 2019 Dec 17;14(24):2025-2033. doi: 10.1002/cmdc.201900465. Epub 2019 Nov.
4. Keech A., Buhmeyer J.I., Kolt R. The Role of Colostrum Proline-Rich Polypeptides in Human Immunological and Neurological Health. In: Waynant R., Tata D.B. (eds) Proceedings of Light-Activated Tissue Regeneration and Therapy Conference. Lecture Notes in Electrical Engineering. 2008;12. Springer, Boston, MA.
5. Lawrence HS. Transfer factor in cellular immunity. The Harvey Lectures, Series.1974;68: 239–350.
6. Burger DR, Vandenbark AA, Finke P, Vetto RM. De novo appearance of KLH transfer factor following immunization. Cell Immunol.1977; 29: 410–3.
7. Petersen EA, Greenberg LE, Manzara T, Kirkpatrick CH. Murine transfer factor. I. Description of the model and evidence for specificity. J. Immunol. 1981;126: 2480–4.
8. Kirkpatrick CH, Rozzo SJ, Mascali JJ, Merryman CF.  Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens. J. Immunol. 1985; 134: 1723–7.
9. Borkowsky W, Lawrence HS. Deletion of antigen-specific activity from leukocyte dialysates containing transfer factor by antigen-coated polystyrene. J. Immunol. 1981;126: 486–489.
10. Kirkpatrick CH, Rozzo SJ, Mascali JJ. Murine transfer factor. III. Specific interactions between transfer factor and antigen. J. Immunol.1985;135: 4027–33.
11. Lawrence HS.The transfer in humans of delayed hypersensitivity to streptococcal M substance and to tuberculin with disrupted leukocytes. J. Clin. Invest. 1955; 34: 219–232.
12. Janusz M1, Zabłocka A. Colostral proline-rich polypeptides--immunoregulatory properties and prospects of therapeutic use in Alzheimer's disease. Curr Alzheimer Res. 2010 Jun;7(4):323-33.
13. Zabłocka A, Janusz M, Rybka K, Wirkus-Romanowska I, Kupryszewski G, Lisowski J.
Cytokine-inducing activity of a proline-rich polypeptide complex (PRP) from ovine colostrum and its active nonapeptide fragment analogs. Eur Cytokine Netw. 2001 Jul-Sep;12(3):462-7.
14. Inglot AD, Janusz M, Lisowski J.  Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes. Arch Immunol Ther Exp (Warsz). 1996;44(4):215-24.
15. Błach-Olszewska Z, Janusz M.Stimulatory effect of ovine colostrinine (a proline-rich polypeptide) on interferons and tumor necrosis factor production by murine resident peritoneal cells. Arch Immunol Ther Exp (Warsz). 1997;45(1):43-7.
16. Zaczyńska E, Broniarek E, Błach-Olszewska Z.  Spontaneous and lipopolysaccharide-induced tumor necrosis factor alpha and interferon beta production by resident peritoneal cells of mice: effect of sex, age and strain. Arch Immunol Ther Exp (Warsz). 1993;41(1):67-71.
17. Janusz M, Starościk K, Zimecki M, Wieczorek Z, Lisowski J. A proline-rich polypeptide (PRP) with immunoregulatory properties isolated from ovine colostrum. Murine thymocytes have on their surface a receptor specific for PRP.Arch Immunol Ther Exp (Warsz). 1986;34(4):427-36.